<?xml version="1.0" encoding="UTF-8"?>
<OAI-PMH xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/ http://www.openarchives.org/OAI/2.0/OAI-PMH.xsd">
  <responseDate>2024-05-03T03:16:32Z</responseDate>
  <request verb="GetRecord" identifier="oai:pubmedcentral.nih.gov:6106425" metadataPrefix="pmc">https:/www.ncbi.nlm.nih.gov/pmc/oai/oai.cgi</request>
  <GetRecord>
    <record>
      <header>
        <identifier>oai:pubmedcentral.nih.gov:6106425</identifier>
        <datestamp>2018-09-01</datestamp>
        <setSpec>eid</setSpec>
        <setSpec>pmc-open</setSpec>
      </header>
      <metadata>
        <article xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xsi:schemaLocation="https://jats.nlm.nih.gov/ns/archiving/1.3/ https://jats.nlm.nih.gov/archiving/1.3/xsd/JATS-archivearticle1-3.xsd" dtd-version="1.3" xml:lang="en" article-type="brief-report">
          <processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats">
            <restricted-by>pmc</restricted-by>
          </processing-meta>
          <front>
            <journal-meta>
              <journal-id journal-id-type="nlm-ta">Emerg Infect Dis</journal-id>
              <journal-id journal-id-type="iso-abbrev">Emerg Infect Dis</journal-id>
              <journal-id journal-id-type="publisher-id">EID</journal-id>
              <journal-title-group>
                <journal-title>Emerging Infectious Diseases</journal-title>
              </journal-title-group>
              <issn pub-type="ppub">1080-6040</issn>
              <issn pub-type="epub">1080-6059</issn>
              <publisher>
                <publisher-name>Centers for Disease Control and Prevention</publisher-name>
              </publisher>
            </journal-meta>
            <article-meta>
              <article-id pub-id-type="accession">PMC6106425</article-id>
              <article-id pub-id-type="pmcid">PMC6106425</article-id>
              <article-id pub-id-type="pmc-uid">6106425</article-id>
              <article-id pub-id-type="pmid">29882740</article-id>
              <article-id pub-id-type="pmid">29882740</article-id>
              <article-id pub-id-type="publisher-id">18-0233</article-id>
              <article-id pub-id-type="doi">10.3201/eid2409.180233</article-id>
              <article-categories>
                <subj-group subj-group-type="heading">
                  <subject>Dispatch</subject>
                </subj-group>
                <subj-group subj-group-type="article-type">
                  <subject>Dispatch</subject>
                </subj-group>
                <subj-group subj-group-type="TOC-title">
                  <subject>Use of Favipiravir to Treat Lassa Virus Infection in Macaques</subject>
                </subj-group>
              </article-categories>
              <title-group>
                <article-title>Use of Favipiravir to Treat Lassa Virus Infection in Macaques</article-title>
                <alt-title alt-title-type="running-head">Favipiravir to Treat Lassa Virus, Macaques</alt-title>
                <alt-title alt-title-type="running-head">Keywords: Lassa virus, antiviral, favipiravir, treatment, viruses, macaques</alt-title>
              </title-group>
              <contrib-group>
                <contrib contrib-type="author">
                  <name>
                    <surname>Rosenke</surname>
                    <given-names>Kyle</given-names>
                  </name>
                </contrib>
                <contrib contrib-type="author" corresp="yes">
                  <name>
                    <surname>Feldmann</surname>
                    <given-names>Heinz</given-names>
                  </name>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Westover</surname>
                    <given-names>Jonna B.</given-names>
                  </name>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Hanley</surname>
                    <given-names>Patrick William</given-names>
                  </name>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Martellaro</surname>
                    <given-names>Cynthia</given-names>
                  </name>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Feldmann</surname>
                    <given-names>Friederike</given-names>
                  </name>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Saturday</surname>
                    <given-names>Greg</given-names>
                  </name>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Lovaglio</surname>
                    <given-names>Jamie</given-names>
                  </name>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Scott</surname>
                    <given-names>Dana P.</given-names>
                  </name>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Furuta</surname>
                    <given-names>Yousuke</given-names>
                  </name>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Komeno</surname>
                    <given-names>Takashi</given-names>
                  </name>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Gowen</surname>
                    <given-names>Brian B.</given-names>
                  </name>
                </contrib>
                <contrib contrib-type="author" corresp="yes">
                  <name>
                    <surname>Safronetz</surname>
                    <given-names>David</given-names>
                  </name>
                </contrib>
                <aff id="aff1">National Institutes of Health, Hamilton, Montana, USA (K. Rosenke, H. Feldmann, P.W. Hanley, C. Martellaro, F. Feldmann, G. Saturday, J. Lovaglio, D.P. Scott); </aff>
                <aff id="aff2">University of Manitoba, Winnipeg, Manitoba, Canada (H. Feldmann, D. Safronetz); </aff>
                <aff id="aff3">Utah State University, Logan, Utah, USA (J.B. Westover, B.B. Gowen); </aff>
                <aff id="aff4">Toyama Chemical Co., Ltd., Toyama, Japan (Y. Furuta, T. Komeno); </aff>
                <aff id="aff5">Public Health Agency of Canada, Winnipeg (D. Safronetz)</aff>
              </contrib-group>
              <author-notes>
                <corresp id="cor1">Address for correspondence: Heinz Feldmann, National Institutes of Health, Laboratory of Virology, Rocky Mountain Laboratories, 903 S 4th St, Hamilton, MT 59840, USA; email: <email xlink:href="feldmannh@niaid.nih.gov">feldmannh@niaid.nih.gov</email>; David Safronetz, National Microbiology Laboratory, PHAC, Viral Zoonoses, 1015 Arlington St, Winnipeg, MB R3E 3R2, Canada; email: <email xlink:href="david.safronetz@phac-aspc.gc.ca">david.safronetz@phac-aspc.gc.ca</email></corresp>
              </author-notes>
              <pub-date pub-type="ppub">
                <month>9</month>
                <year>2018</year>
              </pub-date>
              <volume>24</volume>
              <issue>9</issue>
              <fpage>1696</fpage>
              <lpage>1699</lpage>
              <permissions>
                <license>
                  <ali:license_ref specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref>
                  <license-p>This is a publication of the U.S. Government. This publication is in the public domain and is therefore without copyright. All text from this work may be reprinted freely. Use of these materials should be properly cited.</license-p>
                </license>
              </permissions>
              <abstract>
                <p>Lassa virus, the cause of Lassa fever in humans, is endemic to West Africa. Treatment of Lassa fever is primarily supportive, although ribavirin has shown limited efficacy if administered early during infection. We tested favipiravir in Lassa virus–viremic macaques and found that 300 mg/kg daily for 2 weeks successfully treated infection.</p>
              </abstract>
            </article-meta>
          </front>
          <body>
            <p>Lassa virus (LASV; family <italic>Arenaviridae</italic>, genus <italic>Mammarenavirus</italic>) is the etiologic agent of the severe hemorrhagic disease Lassa fever. Annually, ≈300,000 persons become infected with LASV, 20% of which experience life-threatening clinical manifestations including edema, hemorrhage, and multiorgan failure, resulting in an estimated 5,000 deaths (<xref rid="R1" ref-type="bibr"><italic>1</italic></xref>). Most human infections are acquired from the natural rodent reservoir, the multimammate rat (<italic>Mastomys natalensis</italic>). Human-to-human transmission, mostly nosocomial, occurs (<xref rid="R1" ref-type="bibr"><italic>1</italic></xref>). LASV has a relatively well-defined region of endemicity exclusive to West Africa. Incidence of LASV infections is highest in Nigeria, Sierra Leone, Liberia, and Guinea, although sporadic cases and moderate outbreaks of Lassa fever have been documented in many other West Africa nations (<xref rid="SD1" ref-type="supplementary-material">Technical Appendix </xref>Figure 1) (<xref rid="R2" ref-type="bibr"><italic>2</italic></xref>). Over several decades, importation of Lassa fever into Europe, Asia, and the Americas has increased (<xref rid="R2" ref-type="bibr"><italic>2</italic></xref>).</p>
            <p>Treatment of Lassa fever is largely supportive, although ribavirin is used off label, despite side effects and limited efficacy data (<xref rid="R3" ref-type="bibr"><italic>3</italic></xref>). Recently, the antiviral favipiravir (T-705; 6-fluoro-3-hydroxy-2-pyrazinecarboxamide) has gained attention as a broad-spectrum antiviral drug against RNA viruses (<xref rid="R4" ref-type="bibr"><italic>4</italic></xref>) including LASV; initial studies using small animal models have been conducted (<xref rid="R5" ref-type="bibr"><italic>5</italic></xref>,<xref rid="R6" ref-type="bibr"><italic>6</italic></xref>). We assessed the antiviral efficacy of favipiravir in LASV-infected cynomolgus macaques; this animal model reliably recapitulates several hallmarks of Lassa fever infection in humans (<xref rid="R7" ref-type="bibr"><italic>7</italic></xref>).</p>
            <sec sec-type="other1">
              <title>The Study</title>
              <p>We randomly divided 8 female cynomolgus macaques (<italic>Macaca fascicularis</italic>) into 2 groups of 4 each (treatment and control) and injected each animal intramuscularly with a lethal dose of LASV, strain Josiah (1 × 10<sup>4</sup> 50% tissue culture infective dose [TCID<sub>50</sub>]) (<xref rid="T1" ref-type="table">Table</xref>). Treatment began at 4 days postinfection (dpi), 1 day after the onset of viremia (<xref rid="R7" ref-type="bibr"><italic>7</italic></xref>). The initial treatment (300 mg/kg favipiravir) was administered intravenously; subsequent treatments (300 mg/kg favipiravir every 24 h for 13 d) were administered subcutaneously. The dosage was based on the successful treatment of Lassa fever in guinea pigs (<xref rid="R5" ref-type="bibr"><italic>5</italic></xref>). To avoid the confounding effects of ribavirin, we did not give it in combination. LASV-infected control animals received an equivalent volume of vehicle by the same route and schedule. Animals were assessed twice daily; physical examinations, including hematologic, blood chemistry, and virologic assessments, were conducted regularly.</p>
              <table-wrap position="float" id="T1">
                <label>Table</label>
                <caption>
                  <title>Study design for treatment of Lassa virus infection in cynomolgus macaques*</title>
                </caption>
                <table frame="hsides" rules="groups">
                  <col width="58" span="1"/>
                  <col width="49" span="1"/>
                  <col width="58" span="1"/>
                  <col width="81" span="1"/>
                  <col width="81" span="1"/>
                  <col width="90" span="1"/>
                  <col width="63" span="1"/>
                  <thead>
                    <tr>
                      <th valign="bottom" align="left" scope="col" rowspan="1" colspan="1">Study, no. animals</th>
                      <th valign="bottom" align="center" scope="col" rowspan="1" colspan="1">Treatment</th>
                      <th valign="bottom" align="center" scope="col" rowspan="1" colspan="1">Frequency†</th>
                      <th valign="bottom" align="center" scope="col" rowspan="1" colspan="1">Dose, mg/kg</th>
                      <th valign="bottom" align="center" scope="col" rowspan="1" colspan="1">Loading dose, mg/kg</th>
                      <th valign="bottom" align="center" scope="col" rowspan="1" colspan="1">Total daily dose, mg/kg</th>
                      <th valign="bottom" align="center" scope="col" rowspan="1" colspan="1">Survived/total, no.</th>
                    </tr>
                  </thead>
                  <tbody>
                    <tr>
                      <td valign="top" align="left" scope="col" rowspan="1" colspan="1">First</td>
                      <td valign="top" align="left" rowspan="1" colspan="1"/>
                      <td valign="top" align="left" rowspan="1" colspan="1"/>
                      <td valign="top" align="left" rowspan="1" colspan="1"/>
                      <td valign="top" align="left" rowspan="1" colspan="1"/>
                      <td valign="top" align="left" rowspan="1" colspan="1"/>
                      <td valign="top" align="left" rowspan="1" colspan="1"/>
                    </tr>
                    <tr>
                      <td valign="top" align="left" scope="row" rowspan="1" colspan="1"> 4</td>
                      <td valign="top" align="center" rowspan="1" colspan="1">Placebo</td>
                      <td valign="top" align="center" rowspan="1" colspan="1">Every 24 h</td>
                      <td valign="top" align="center" rowspan="1" colspan="1">Volume equivalent</td>
                      <td valign="top" align="center" rowspan="1" colspan="1">Volume equivalent</td>
                      <td valign="top" align="center" rowspan="1" colspan="1">Volume equivalent</td>
                      <td valign="top" align="center" rowspan="1" colspan="1">0/4</td>
                    </tr>
                    <tr>
                      <td valign="top" align="left" scope="row" rowspan="1" colspan="1"> 4<hr/></td>
                      <td valign="top" align="center" rowspan="1" colspan="1">Favipiravir<hr/></td>
                      <td valign="top" align="center" rowspan="1" colspan="1">Every 24 h<hr/></td>
                      <td valign="top" align="center" rowspan="1" colspan="1">300<hr/></td>
                      <td valign="top" align="center" rowspan="1" colspan="1">300<hr/></td>
                      <td valign="top" align="center" rowspan="1" colspan="1">300<hr/></td>
                      <td valign="top" align="center" rowspan="1" colspan="1">4/4<hr/></td>
                    </tr>
                    <tr>
                      <td valign="top" align="left" scope="col" rowspan="1" colspan="1">Second</td>
                      <td valign="top" align="left" rowspan="1" colspan="1"/>
                      <td valign="top" align="left" rowspan="1" colspan="1"/>
                      <td valign="top" align="left" rowspan="1" colspan="1"/>
                      <td valign="top" align="left" rowspan="1" colspan="1"/>
                      <td valign="top" align="left" rowspan="1" colspan="1"/>
                      <td valign="top" align="left" rowspan="1" colspan="1"/>
                    </tr>
                    <tr>
                      <td valign="top" align="left" scope="row" rowspan="1" colspan="1"> 4</td>
                      <td valign="top" align="center" rowspan="1" colspan="1">Placebo</td>
                      <td valign="top" align="center" rowspan="1" colspan="1">Every 8 h</td>
                      <td valign="top" align="center" rowspan="1" colspan="1">Volume equivalent.</td>
                      <td valign="top" align="center" rowspan="1" colspan="1">Volume equivalent</td>
                      <td valign="top" align="center" rowspan="1" colspan="1">Volume equivalent</td>
                      <td valign="top" align="center" rowspan="1" colspan="1">0/4</td>
                    </tr>
                    <tr>
                      <td valign="top" align="left" scope="row" rowspan="1" colspan="1"> 4</td>
                      <td valign="top" align="center" rowspan="1" colspan="1">Favipiravir</td>
                      <td valign="top" align="center" rowspan="1" colspan="1">Every 8 h</td>
                      <td valign="top" align="center" rowspan="1" colspan="1">50</td>
                      <td valign="top" align="center" rowspan="1" colspan="1">300</td>
                      <td valign="top" align="center" rowspan="1" colspan="1">150</td>
                      <td valign="top" align="center" rowspan="1" colspan="1">0/4</td>
                    </tr>
                  </tbody>
                </table>
                <table-wrap-foot>
                  <p>*All animals were challenged with a previously determined lethal dose of 10<sup>4</sup> 50% tissue culture infective dose of Lassa virus (strain Josiah) via intramuscular injection. At day 4 after infection, a time coinciding with the earliest onset of detectable viremia, treatment with placebo or drug was initiated by intravenous injection of the loading dose followed by daily (days 5–17) subcutaneous dosing. Animals were examined daily for clinical signs of disease, and samples were taken for hematologic, blood chemistry, and virologic analyses at 12 times throughout the study, beginning on the day of virus challenge and ending on day 56 after infection. †For 14 d.</p>
                </table-wrap-foot>
              </table-wrap>
              <p>Reduced activity and appetite, probably resulting from being anesthetized daily, was noted early in animals in both groups (<xref rid="F1" ref-type="fig">Figure 1</xref>, panel A). At 6 dpi (2 d after treatment began), clinical scores for 3 of 4 animals in the treatment group plateaued and remained consistent for the remainder of the study. Although the score for the remaining animal was higher, all favipiravir-treated animals survived LASV challenge (p&lt;0.01; <xref rid="F1" ref-type="fig">Figure 1</xref>, panel B). In contrast, clinical scores for the control group increased dramatically after 8 dpi; all control animals displayed anorexia, hunched posture, piloerection, and lethargy (<xref rid="F1" ref-type="fig">Figure 1</xref>, panel A). The control animals reached the humane endpoint and were euthanized on 10, 11, and 12 dpi (<xref rid="F1" ref-type="fig">Figure 1</xref>, panel B).</p>
              <fig position="float" id="F1" fig-type="figure">
                <label>Figure 1</label>
                <caption>
                  <p>Effect of daily favipiravir treatments on morbidity and mortality rates, viral loads, and selected blood chemistry and hematology values during the course of the efficacy study in cynomolgus macaques challenged with 10<sup>4</sup> TCID<sub>50</sub> of Lassa virus. Groups of 4 animals each were given 300 mg/kg/d of favipiravir or placebo for 14 consecutive days, beginning on day 4 postinfection. A) Daily clinical scores (dotted line indicates euthanasia score of 35). B) Survival curve (*p&lt;0.01 compared with placebo-treated animals by the Mantel-Cox log-rank test). C) Viremia as assessed by TCID<sub>50</sub> assay. D) Alanine aminotransferase levels. E) Aspartate aminotransferase levels. F) Albumin levels. G) Total protein levels. H) Platelet levels. TCID<sub>50</sub>, 50% tissue culture infective dose.</p>
                </caption>
                <graphic xlink:href="18-0233-F1" position="float"/>
              </fig>
              <p>Although we detected viral RNA by quantitative PCR as early as 3 dpi (online Technical Appendix <xref rid="F2" ref-type="fig">Figure 2</xref>, panel A), at no time was infectious LASV isolated from blood (<xref rid="F1" ref-type="fig">Figure 1</xref>, panel C) or postmortem tissue samples (data not shown) from animals in the favipiravir group. However, in the control animals, increased liver enzyme levels were detected at 6 dpi, coinciding with infectious LASV (<xref rid="F1" ref-type="fig">Figure 1</xref>, panels D, E). One animal in the favipiravir group demonstrated moderately increased levels of alanine aminotransferase and aspartate aminotransferase at 6–12 dpi, which resolved after treatment cessation. In the control animals, albumin and total protein levels decreased dramatically throughout LASV infection; in the favipiravir-treated animals, these levels displayed a more moderate decrease before returning toward reference levels (<xref rid="F1" ref-type="fig">Figure 1</xref>, panels F, G).</p>
              <fig position="float" id="F2" fig-type="figure">
                <label>Figure 2</label>
                <caption>
                  <p>Histologic and in situ hybridization analyses of livers from cynomolgus macaques infected with Lassa virus (LASV) (1 × 10<sup>4</sup> 50% tissue culture infective dose [TCID<sub>50</sub>]) and treated 1 time daily with favipiravir (treated) or vehicle only (control). A–B) Histologic analyses. A) Control, showing multifocal neutrophilic infiltrates with hepatocyte necrosis and degeneration (original magnification ×40). Inset shows hepatocyte necrosis (original magnification ×400). B) Treated, showing essentially healthy hepatic tissue (original magnification ×40). Inset shows healthy hepatic tissue (original magnification ×400). C–D) In situ hybridization analyses. C) Control, showing multifocal and coalescing viral RNA detected within hepatocytes (original magnification ×100). D) Treated, showing no viral RNA detected (original magnification ×100). </p>
                </caption>
                <graphic xlink:href="18-0233-F2" position="float"/>
              </fig>
              <p>Hematologic profiles were less uniform between the 2 groups, although we observed several abnormalities previously associated with LASV infection (<xref rid="SD1" ref-type="supplementary-material">Technical Appendix </xref>Figure 3). After an initial increase, platelet counts in the control animals consistently decreased until euthanasia. In 2 of the favipiravir-treated animals, a similar increase was noted initially; however, a marked decrease occurred at 6 dpi (<xref rid="F1" ref-type="fig">Figure 1</xref>, panel H). Platelet levels rebounded by 9 dpi and continued to increase. In addition, all 4 favipiravir-treated animals had lipemia (&gt;301 mg/dL) during the treatment phase of the study (4–18 dpi).</p>
              <p>Histopathologic examination of livers from control animals demonstrated hepatitis with neutrophil invasion and substantial steatosis, consistent with Lassa fever in this model (<xref rid="F2" ref-type="fig">Figure 2</xref>, panel A) (<xref rid="R7" ref-type="bibr"><italic>7</italic></xref>). In contrast, livers from favipiravir-treated animals showed no abnormalities (<xref rid="F2" ref-type="fig">Figure 2</xref>, panel B). In situ hybridization detected LASV RNA within hepatocytes of control animals but not treated animals (<xref rid="F2" ref-type="fig">Figure 2</xref>, panels C, D).</p>
            </sec>
            <sec sec-type="conclusions">
              <title>Conclusions</title>
              <p>Over the past 3 years, total numbers of Lassa fever cases and case-fatality rates among humans have increased (<xref rid="R8" ref-type="bibr"><italic>8</italic></xref>). The current Lassa fever outbreak in Nigeria and Benin continues to show large numbers of Lassa fever cases and case-fatality rates &gt;30% (<xref rid="R8" ref-type="bibr"><italic>8</italic></xref>), again highlighting the lack of available treatments. Furthermore, the recent person-to-person transmission of LASV in Germany (<xref rid="R9" ref-type="bibr"><italic>9</italic></xref>) serves as a reminder that Lassa fever is of global health concern.</p>
              <p>Lassa fever patients are largely managed by supportive care in combination with ribavirin (<xref rid="R3" ref-type="bibr"><italic>3</italic></xref>). Experimental efficacy of ribavirin was initially tested in a Lassa fever rhesus macaque model in which intramuscular injections 3 times daily for 14 days improved survival rates (<xref rid="R10" ref-type="bibr"><italic>10</italic></xref>). In clinical trials in Sierra Leone, both oral and intravenous ribavirin increased survival rates of Lassa fever patients (<xref rid="R11" ref-type="bibr"><italic>11</italic></xref>). Oral dosing of ribavirin has since remained the standard of treatment for Lassa fever, despite unproven efficacy from clinical studies (<xref rid="R3" ref-type="bibr"><italic>3</italic></xref><italic>,</italic><xref rid="R12" ref-type="bibr"><italic>12</italic></xref>). Moreover, side effects of ribavirin therapy have resulted in noncompliance (<xref rid="R12" ref-type="bibr"><italic>12</italic></xref>).</p>
              <p>The successful daily administration of favipiravir to macaques at an elevated dosing regimen of 300 mg/kg/d may partially explain the transient thrombocytopenia, elevated liver enzyme levels, and lipemia found in this study. Experimentally, favipiravir is a well-known broad-spectrum antiviral drug with in vitro inhibitory activity against a multitude of RNA viruses (<xref rid="R4" ref-type="bibr"><italic>4</italic></xref>). In Japan, favipiravir is approved for influenza treatment; in the United States, phase 3 clinical trials for the same indication have been completed (<xref rid="R4" ref-type="bibr"><italic>4</italic></xref>). During the West Africa Ebola outbreak, favipiravir was administered to humans on an emergency basis under a different dosing regimen, but effectiveness was limited (<xref rid="R13" ref-type="bibr"><italic>13</italic></xref>). We therefore designed a second study that more closely followed the dosing in the Ebola trial (50 mg/kg every 8 h) (<xref rid="R13" ref-type="bibr"><italic>13</italic></xref>). However, this multiple dose per day format failed to protect cynomolgus macaques from Lassa fever and did not alter disease progression (<xref rid="T1" ref-type="table">Table</xref>; <xref rid="SD1" ref-type="supplementary-material">Technical Appendix </xref>Figure 1, panel B, and Figure 4, panels A–D). Of note, the high-dose favipiravir therapy in macaques successfully abated the pathophysiologic parameters associated with LASV infection, resulting in survival. These results suggest that low doses of favipiravir have limited therapeutic effect, whereas higher doses are therapeutic and will improve clinical outcomes.</p>
              <p>Favipiravir was recently administered in combination with ribavirin to successfully treat Lassa fever in 2 human patients. Although it is not possible to determine how effective favipiravir was in controlling these 2 cases, administration reduced viremia in both patients (<xref rid="R9" ref-type="bibr"><italic>9</italic></xref>). Combination therapy with favipiravir and ribavirin in immunocompromised mice with LASV infection showed efficacy with suboptimal doses of each drug (<xref rid="R6" ref-type="bibr"><italic>6</italic></xref>). The synergistic effect of the 2 compounds is also supported by several other studies in rodents (<xref rid="R14" ref-type="bibr"><italic>14</italic></xref>). Recently, human monoclonal antibody therapy protected cynomolgus macaques from LASV infection (<xref rid="R15" ref-type="bibr"><italic>15</italic></xref>). Combination therapy with favipiravir may be a future therapeutic strategy (<xref rid="R15" ref-type="bibr"><italic>15</italic></xref>). On the basis of our findings, improved favipiravir tolerability in humans (<xref rid="R4" ref-type="bibr"><italic>4</italic></xref>), availability of an oral formulation, and its advanced preclinical status (according to the US Food and Drug Administration), we recommend that favipiravir enter clinical trials as a treatment for Lassa fever.</p>
            </sec>
            <sec sec-type="supplementary-material">
              <supplementary-material id="SD1" position="float" content-type="local-data">
                <caption>
                  <title>Technical Appendix</title>
                  <p>Additional information concerning study design and technical details pertinent to methods; supplemental data for results of the experiments described. </p>
                </caption>
                <media xlink:href="18-0233-Techapp-s1.pdf" id="d95e459" position="anchor"/>
              </supplementary-material>
            </sec>
          </body>
          <back>
            <ack>
              <title>Acknowledgments</title>
              <p>We thank the Rocky Mountain Veterinary Branch of the National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH), for animal care and veterinary clinical support.</p>
              <p>The study was supported in part by the Intramural Research Program, NIAID, NIH, and the Rocky Mountain Regional Center of Excellence for Biodefense and Emerging Infectious Disease Research, NIAID, NIH (subaward to B.B.G. as part of NIH grant U54 AI-065357). The funders of the study were not involved in the analysis, interpretation, or discussions associated with publication of these data.</p>
              <p>Y.F. and T.K. are employees of Toyama Chemical Co., the manufacturers of favipiravir. All other authors declare no conflict of interest.</p>
            </ack>
            <fn-group>
              <fn fn-type="citation">
                <p><italic>Suggested citation for this article</italic>: Rosenke K, Feldmann H, Westover JB, Hanley PW, Martellaro C, Feldmann F, et al. Use of favipiravir to treat Lassa virus infection in macaques. Emerg Infect Dis. 2018 Sep [<italic>date cited</italic>]. <ext-link xlink:href="https://doi.org/10.3201/eid2409.180233" ext-link-type="uri">https://doi.org/10.3201/eid2409.180233</ext-link></p>
              </fn>
            </fn-group>
            <bio id="d95e475">
              <p>Dr. Rosenke is a microbiologist in the Laboratory of Virology, NIAID, NIH. His research interests are the epidemiology, ecology, pathogenesis, and treatment of emerging viral diseases.</p>
            </bio>
            <ref-list>
              <title>References</title>
              <ref id="R1">
                <label>1. </label>
                <mixed-citation publication-type="journal"><string-name><surname>Yun</surname><given-names>NE</given-names></string-name>, <string-name><surname>Walker</surname><given-names>DH</given-names></string-name>. <article-title>Pathogenesis of Lassa fever.</article-title><source>Viruses</source>. <year>2012</year>;<volume>4</volume>:<fpage>2031</fpage>–<lpage>48</lpage>. <pub-id pub-id-type="doi">10.3390/v4102031</pub-id><?supplied-pmid 23202452?><pub-id pub-id-type="pmid">23202452</pub-id></mixed-citation>
              </ref>
              <ref id="R2">
                <label>2. </label>
                <mixed-citation publication-type="journal"><string-name><surname>Sogoba</surname><given-names>N</given-names></string-name>, <string-name><surname>Feldmann</surname><given-names>H</given-names></string-name>, <string-name><surname>Safronetz</surname><given-names>D</given-names></string-name>. <article-title>Lassa fever in West Africa: evidence for an expanded region of endemicity.</article-title><source>Zoonoses Public Health</source>. <year>2012</year>;<volume>59</volume>(<issue>Suppl 2</issue>):<fpage>43</fpage>–<lpage>7</lpage>. <pub-id pub-id-type="doi">10.1111/j.1863-2378.2012.01469.x</pub-id><?supplied-pmid 22958249?><pub-id pub-id-type="pmid">22958249</pub-id></mixed-citation>
              </ref>
              <ref id="R3">
                <label>3. </label>
                <mixed-citation publication-type="journal"><string-name><surname>Bausch</surname><given-names>DG</given-names></string-name>, <string-name><surname>Hadi</surname><given-names>CM</given-names></string-name>, <string-name><surname>Khan</surname><given-names>SH</given-names></string-name>, <string-name><surname>Lertora</surname><given-names>JJ</given-names></string-name>. <article-title>Review of the literature and proposed guidelines for the use of oral ribavirin as postexposure prophylaxis for Lassa fever.</article-title><source>Clin Infect Dis</source>. <year>2010</year>;<volume>51</volume>:<fpage>1435</fpage>–<lpage>41</lpage>. <pub-id pub-id-type="doi">10.1086/657315</pub-id><?supplied-pmid 21058912?><pub-id pub-id-type="pmid">21058912</pub-id></mixed-citation>
              </ref>
              <ref id="R4">
                <label>4. </label>
                <mixed-citation publication-type="journal"><string-name><surname>Furuta</surname><given-names>Y</given-names></string-name>, <string-name><surname>Gowen</surname><given-names>BB</given-names></string-name>, <string-name><surname>Takahashi</surname><given-names>K</given-names></string-name>, <string-name><surname>Shiraki</surname><given-names>K</given-names></string-name>, <string-name><surname>Smee</surname><given-names>DF</given-names></string-name>, <string-name><surname>Barnard</surname><given-names>DL</given-names></string-name>. <article-title>Favipiravir (T-705), a novel viral RNA polymerase inhibitor.</article-title><source>Antiviral Res</source>. <year>2013</year>;<volume>100</volume>:<fpage>446</fpage>–<lpage>54</lpage>. <pub-id pub-id-type="doi">10.1016/j.antiviral.2013.09.015</pub-id><?supplied-pmid 24084488?><pub-id pub-id-type="pmid">24084488</pub-id></mixed-citation>
              </ref>
              <ref id="R5">
                <label>5. </label>
                <mixed-citation publication-type="journal"><string-name><surname>Safronetz</surname><given-names>D</given-names></string-name>, <string-name><surname>Rosenke</surname><given-names>K</given-names></string-name>, <string-name><surname>Westover</surname><given-names>JB</given-names></string-name>, <string-name><surname>Martellaro</surname><given-names>C</given-names></string-name>, <string-name><surname>Okumura</surname><given-names>A</given-names></string-name>, <string-name><surname>Furuta</surname><given-names>Y</given-names></string-name>, <etal>et al.</etal><article-title>The broad-spectrum antiviral favipiravir protects guinea pigs from lethal Lassa virus infection post-disease onset.</article-title><source>Sci Rep</source>. <year>2015</year>;<volume>5</volume>:<fpage>14775</fpage>. <pub-id pub-id-type="doi">10.1038/srep14775</pub-id><?supplied-pmid 26456301?><pub-id pub-id-type="pmid">26456301</pub-id></mixed-citation>
              </ref>
              <ref id="R6">
                <label>6. </label>
                <mixed-citation publication-type="journal"><string-name><surname>Oestereich</surname><given-names>L</given-names></string-name>, <string-name><surname>Rieger</surname><given-names>T</given-names></string-name>, <string-name><surname>Lüdtke</surname><given-names>A</given-names></string-name>, <string-name><surname>Ruibal</surname><given-names>P</given-names></string-name>, <string-name><surname>Wurr</surname><given-names>S</given-names></string-name>, <string-name><surname>Pallasch</surname><given-names>E</given-names></string-name>, <etal>et al.</etal><article-title>Efficacy of favipiravir alone and in combination with ribavirin in a lethal, immunocompetent mouse model of Lassa fever.</article-title><source>J Infect Dis</source>. <year>2016</year>;<volume>213</volume>:<fpage>934</fpage>–<lpage>8</lpage>. <pub-id pub-id-type="doi">10.1093/infdis/jiv522</pub-id><?supplied-pmid 26531247?><pub-id pub-id-type="pmid">26531247</pub-id></mixed-citation>
              </ref>
              <ref id="R7">
                <label>7. </label>
                <mixed-citation publication-type="journal"><string-name><surname>Hensley</surname><given-names>LE</given-names></string-name>, <string-name><surname>Smith</surname><given-names>MA</given-names></string-name>, <string-name><surname>Geisbert</surname><given-names>JB</given-names></string-name>, <string-name><surname>Fritz</surname><given-names>EA</given-names></string-name>, <string-name><surname>Daddario-DiCaprio</surname><given-names>KM</given-names></string-name>, <string-name><surname>Larsen</surname><given-names>T</given-names></string-name>, <etal>et al.</etal><article-title>Pathogenesis of Lassa fever in cynomolgus macaques.</article-title><source>Virol J</source>. <year>2011</year>;<volume>8</volume>:<fpage>205</fpage>. <pub-id pub-id-type="doi">10.1186/1743-422X-8-205</pub-id><?supplied-pmid 21548931?><pub-id pub-id-type="pmid">21548931</pub-id></mixed-citation>
              </ref>
              <ref id="R8">
                <label>8. </label>
                <mixed-citation publication-type="webpage"><collab>World Health Organization</collab>. Weekly bulletin on outbreaks and other emergencies [cited 2018 Feb 5]. <ext-link xlink:href="http://apps.who.int/iris/bitstream/handle/10665/260122/OEW5-2701222018.pdf;jsessionid=D19D5C05BE101587B3AC601D56544764?sequence=1" ext-link-type="uri">http://apps.who.int/iris/bitstream/handle/10665/260122/OEW5-2701222018.pdf;jsessionid=D19D5C05BE101587B3AC601D56544764?sequence=1</ext-link></mixed-citation>
              </ref>
              <ref id="R9">
                <label>9. </label>
                <mixed-citation publication-type="journal"><string-name><surname>Raabe</surname><given-names>VN</given-names></string-name>, <string-name><surname>Kann</surname><given-names>G</given-names></string-name>, <string-name><surname>Ribner</surname><given-names>BS</given-names></string-name>, <string-name><surname>Morales</surname><given-names>A</given-names></string-name>, <string-name><surname>Varkey</surname><given-names>JB</given-names></string-name>, <string-name><surname>Mehta</surname><given-names>AK</given-names></string-name>, <etal>et al.</etal>; <collab>Emory Serious Communicable Diseases Unit</collab>. <article-title>Emory Serious Communicable Diseases Unit. Favipiravir and ribavirin treatment of epidemiologically linked cases of Lassa fever.</article-title><source>Clin Infect Dis</source>. <year>2017</year>;<volume>65</volume>:<fpage>855</fpage>–<lpage>9</lpage>. <pub-id pub-id-type="doi">10.1093/cid/cix406</pub-id><?supplied-pmid 29017278?><pub-id pub-id-type="pmid">29017278</pub-id></mixed-citation>
              </ref>
              <ref id="R10">
                <label>10. </label>
                <mixed-citation publication-type="journal"><string-name><surname>Jahrling</surname><given-names>PB</given-names></string-name>, <string-name><surname>Hesse</surname><given-names>RA</given-names></string-name>, <string-name><surname>Eddy</surname><given-names>GA</given-names></string-name>, <string-name><surname>Johnson</surname><given-names>KM</given-names></string-name>, <string-name><surname>Callis</surname><given-names>RT</given-names></string-name>, <string-name><surname>Stephen</surname><given-names>EL</given-names></string-name>. <article-title>Lassa virus infection of rhesus monkeys: pathogenesis and treatment with ribavirin.</article-title><source>J Infect Dis</source>. <year>1980</year>;<volume>141</volume>:<fpage>580</fpage>–<lpage>9</lpage>. <pub-id pub-id-type="doi">10.1093/infdis/141.5.580</pub-id><?supplied-pmid 6768812?><pub-id pub-id-type="pmid">6768812</pub-id></mixed-citation>
              </ref>
              <ref id="R11">
                <label>11. </label>
                <mixed-citation publication-type="journal"><string-name><surname>McCormick</surname><given-names>JB</given-names></string-name>, <string-name><surname>King</surname><given-names>IJ</given-names></string-name>, <string-name><surname>Webb</surname><given-names>PA</given-names></string-name>, <string-name><surname>Scribner</surname><given-names>CL</given-names></string-name>, <string-name><surname>Craven</surname><given-names>RB</given-names></string-name>, <string-name><surname>Johnson</surname><given-names>KM</given-names></string-name>, <etal>et al.</etal><article-title>Lassa fever. Effective therapy with ribavirin.</article-title><source>N Engl J Med</source>. <year>1986</year>;<volume>314</volume>:<fpage>20</fpage>–<lpage>6</lpage>. <pub-id pub-id-type="doi">10.1056/NEJM198601023140104</pub-id><?supplied-pmid 3940312?><pub-id pub-id-type="pmid">3940312</pub-id></mixed-citation>
              </ref>
              <ref id="R12">
                <label>12. </label>
                <mixed-citation publication-type="journal"><string-name><surname>Hadi</surname><given-names>CM</given-names></string-name>, <string-name><surname>Goba</surname><given-names>A</given-names></string-name>, <string-name><surname>Khan</surname><given-names>SH</given-names></string-name>, <string-name><surname>Bangura</surname><given-names>J</given-names></string-name>, <string-name><surname>Sankoh</surname><given-names>M</given-names></string-name>, <string-name><surname>Koroma</surname><given-names>S</given-names></string-name>, <etal>et al.</etal><article-title>Ribavirin for Lassa fever postexposure prophylaxis.</article-title><source>Emerg Infect Dis</source>. <year>2010</year>;<volume>16</volume>:<fpage>2009</fpage>–<lpage>11</lpage>. <pub-id pub-id-type="doi">10.3201/eid1612.100994</pub-id><?supplied-pmid 21122249?><pub-id pub-id-type="pmid">21122249</pub-id></mixed-citation>
              </ref>
              <ref id="R13">
                <label>13. </label>
                <mixed-citation publication-type="journal"><string-name><surname>Sissoko</surname><given-names>D</given-names></string-name>, <string-name><surname>Laouenan</surname><given-names>C</given-names></string-name>, <string-name><surname>Folkesson</surname><given-names>E</given-names></string-name>, <string-name><surname>M’Lebing</surname><given-names>AB</given-names></string-name>, <string-name><surname>Beavogui</surname><given-names>AH</given-names></string-name>, <string-name><surname>Baize</surname><given-names>S</given-names></string-name>, <etal>et al.</etal>; <collab>JIKI Study Group</collab>. <article-title>Experimental treatment with favipiravir for Ebola virus disease (the JIKI Trial): a historically controlled, single-arm proof-of-concept trial in Guinea.</article-title><source>PLoS Med</source>. <year>2016</year>;<volume>13</volume>:<fpage>e1001967</fpage>. <pub-id pub-id-type="doi">10.1371/journal.pmed.1001967</pub-id><?supplied-pmid 26930627?><pub-id pub-id-type="pmid">26930627</pub-id></mixed-citation>
              </ref>
              <ref id="R14">
                <label>14. </label>
                <mixed-citation publication-type="journal"><string-name><surname>Westover</surname><given-names>JB</given-names></string-name>, <string-name><surname>Sefing</surname><given-names>EJ</given-names></string-name>, <string-name><surname>Bailey</surname><given-names>KW</given-names></string-name>, <string-name><surname>Van Wettere</surname><given-names>AJ</given-names></string-name>, <string-name><surname>Jung</surname><given-names>KH</given-names></string-name>, <string-name><surname>Dagley</surname><given-names>A</given-names></string-name>, <etal>et al.</etal><article-title>Low-dose ribavirin potentiates the antiviral activity of favipiravir against hemorrhagic fever viruses.</article-title><source>Antiviral Res</source>. <year>2016</year>;<volume>126</volume>:<fpage>62</fpage>–<lpage>8</lpage>. <pub-id pub-id-type="doi">10.1016/j.antiviral.2015.12.006</pub-id><?supplied-pmid 26711718?><pub-id pub-id-type="pmid">26711718</pub-id></mixed-citation>
              </ref>
              <ref id="R15">
                <label>15. </label>
                <mixed-citation publication-type="journal"><string-name><surname>Mire</surname><given-names>CE</given-names></string-name>, <string-name><surname>Cross</surname><given-names>RW</given-names></string-name>, <string-name><surname>Geisbert</surname><given-names>JB</given-names></string-name>, <string-name><surname>Borisevich</surname><given-names>V</given-names></string-name>, <string-name><surname>Agans</surname><given-names>KN</given-names></string-name>, <string-name><surname>Deer</surname><given-names>DJ</given-names></string-name>, <etal>et al.</etal><article-title>Human-monoclonal-antibody therapy protects nonhuman primates against advanced Lassa fever.</article-title><source>Nat Med</source>. <year>2017</year>;<volume>23</volume>:<fpage>1146</fpage>–<lpage>9</lpage>. <pub-id pub-id-type="doi">10.1038/nm.4396</pub-id><?supplied-pmid 28869611?><pub-id pub-id-type="pmid">28869611</pub-id></mixed-citation>
              </ref>
            </ref-list>
          </back>
        </article>
      </metadata>
    </record>
  </GetRecord>
</OAI-PMH>
